A Phase 4 interventional study of Daptomycin for Injection and Vancomycin (IV) in Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia and S. Aureus Bacteremia, sponsored by Todd C. Lee MD MPH FIDSA. Recruiting at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Todd C. Lee MD MPH FIDSA · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing daptomycin in Bacteremia — 2 open to participants now, 2 under way, none of them phase 3. Daptomycin · Bacteremia.
Among the 14 studies testing daptomycin in Bacteremia, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 4, and was the 13th registered.
298 studies on the registry are indexed under Bacteremia; 50 are open to participants now.
Browse Bacteremia studies →2 of the 14 studies testing daptomycin in Bacteremia are open now, in 4 countries. Recruiting first, the newest first:
West Virginia University · Sites in United States
Ages 18+
By country, each count listing its studies:
Daptomycin: first FDA approval 2003 (CUBICIN), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 39 Bacteremia studies recruiting now, 31 (79%) set no upper age limit and 4 (10%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 300 is above the median of 156 across 156 interventional studies indexed under Bacteremia.
Median enrollment 38 across the 13 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 14 have an industry lead sponsor. The 10 most frequent:
Todd C. Lee MD MPH FIDSA is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Todd C. Lee MD MPH FIDSA has 2 studies filed under Bacteremia — fewer than ten, so there is no comparison to draw.
1 of the studies testing daptomycin in Bacteremia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07148960West Virginia UniversityDoes Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing daptomycin in Bacteremia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:
Inclusion Criteria:
Exclusion Criteria:
Daptomycin given by injection at a dose determined by the treating clinicians but no less than 6mg/kg
Drug: Daptomycin for Injection
Vancomycin given by injection at a dose determined by the treating clinicians to achieve a trough-based or AUC-based target
Drug: Vancomycin (IV)
Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
Desirability of Outcome Ranking (DOOR)
Desirability of Outcome Ranking (DOOR) - an ordinal outcome with 5 levels defined: Rank 1 - Alive without complication Rank 2 - Alive with 1 complication Rank 3 - Alive with 2 complications Rank 4 - Alive with 3 complications Rank 5 - Dead Complications include: 1. Clinical failure: Absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated. 2. Infectious Complications: Including new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of MRSA bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures; change of therapy due to inadequate clinical response. 3. Serious adverse drug event (Common Terminology Criteria class 4) due to study drug OR adverse drug event (classes 1-3) leading to discontinuation of the study drug
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinical failure
Defined as the absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated for its treatment.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Serious Adverse Event or Adverse Event Leading to Discontinuation
Defined as a serious adverse drug event (Common Terminology Criteria for Adverse Events (CTCAE) class 4) presumed due to study drug OR adverse drug event (CTCAE classes 1-3) leading to discontinuation of the study drug
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
All cause mortality
Death from any cause
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Infectious Complications
Defined as change in therapy for inadequate clinical response; new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of MRSA bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures; change of antibiotic therapy due to inadequate clinical response. New implies that the complication was not suspected at enrollment and is not a function of delay to diagnostic testing.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Drug Induced Myostitis
Defined as a creatinine kinase level greater than or equal to 5 times the upper limit of normal
Time frame: Occurring while on therapy up to day 42 from enrollment in SNAP (NCT05137119)
Eosinophilic pneumonia
Defined as the development of symptomatic eosinophilic pneumonia as diagnosed by the treating team in consultation with the appropriate specialists
Time frame: Occurring while on therapy up to day 42 from enrollment in SNAP (NCT05137119)
Plan to share: Undecided — Data sharing policies are dependent on the policies of the SNAP Platform (NCT05137119)
Started Nov 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daptomycin
Todd C. Lee MD MPH FIDSA